Taken from today's CE mark announcement, SM stated:
“Importantly, VitroGro® ECM WILL BE approved for the treatment of all ‘hard to heal’ wounds, primarily venous ulcers. THIS INCLUDES BURNS and acute injuries in patients who have compromised healing, as well as diabetic, venous and pressure ulcers.”
Forgive my ignorance... does this mean that TIS won't have to do any clinical trials of Vitrogro on burns patients or pressure ulcers etc in the EU because treatment of these is being approved by this current CE mark process? Doesn't this now open up another whole market for Vitrogro sales?
Add to My Watchlist
What is My Watchlist?